Enhance the FDA's Postmarketing Drug Surveillance System of Adverse Effects through the Electronic Healthcare Data
*Corresponding Author
:
Xianglin L Du, Division of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, University of Texas Health Science Center at Houston, 1200 Herman Pressler Drive, RAS-E631, Houston, TX 77030, USA, Tel: 713-500-9956, Fax: 713-500-9264, Email: [email protected]
Received Date: Oct 04, 2012 / Accepted Date: Oct 07, 2012 / Published Date: Oct 10, 2012
Abstract
Du XL (2012) Enhance the FDA’s Postmarketing Drug Surveillance System of Adverse Effects through the Electronic Healthcare Data. Epidemiol 2:e104.
Keywords: Postmarketing drug surveillance; Adverse effects; Drug therapy; Electronic healthcare data
Citation: © 2012 Du XL. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Doi: 10.4172/2161-1165.1000e104
Select your language of interest to view the total content in your interested language
Share This Article
Open Access Journals
Article Tools
Article Usage
- Total views: 13214
- [From(publication date): 10-2012 - Sep 29, 2022]
- Breakdown by view type
- HTML page views: 8995
- PDF downloads: 4219
